Botulinum toxin injections in the management of non-neurogenic overactive bladders in children

Onabotulinum toxin A in children with refractory idiopathic overactive bladder: medium-term outcomes

“…McDowell et al [11] used doses of 12 u/kg up to 480U which is the equivalent of 4.8u/kg Botoxâ up to a maximum of 192U. Léon et al [12] assessed eight children with IOAB and through the use of micturition diaries observed that all patients had improvements after BtA and noticed no adverse effects from treatment when using a dose of 8 u/kg of Dysportâ (equivalent to 3.2 u/kg Botoxâ).…”

Adolescence transitional care in neurogenic detrusor overactivity and the use of OnabotulinumtoxinA: A clinical algorithm from an Italian consensus statement

“…Two small retrospective studies focused on the role of aboBNTa in children with NDO. Although, aboBNTa may be a potential therapeutic option for the management of NDO in children resistant to the usual treatments, these studies did not demonstrate a correlation between dose or functional bladder capacity and resolution of incontinence …”

“…Although, aboBNTa may be a potential therapeutic option for the management of NDO in children resistant to the usual treatments, these studies did not demonstrate a correlation between dose or functional bladder capacity and resolution of incontinence. 47,48 Many randomized clinical trials (RCTs) and several review articles support the efficacy and safety of onaBNTa in treating NDO. 2,10 Furthermore, literature has clearly shown the persistence of the therapeutic effect with repeated treatments during the time.…”

Efficacy and safety of intradetrusor onabotulinumtoxinA injection for managing paediatric non-neurogenic overactive bladder: A prospective case-series study

“…Also, Santos et al [22] documented that in patients with OAB/idiopathic detrusor overactivity, 100 U onabotulinumtoxinA injected in 20 sites above the trigone markedly decreased UI, frequency and urgency episodes and improved quality of life. Thereafter, Léon et al [23] reported improvements without any complaints during bladder voiding for 100% of their series of children with non-neurogenic OAB and found OAB disappeared completely after one injection in 67% and repeated injections in 33%, with improved compliance early-on in 50% and at 1-year in 100% of patients. Also, 't Hoen et al [24] reported a success rate of 87.5% with onabotulinumtoxinA 100 U injection in children with therapy-refractory dysfunctional voiding after a median follow-up of 13 months, and found all of these children were no longer daily incontinent and 65.3% of patients became completely dry.…”